Clinical Trials · NCT00040027
Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- SciClone Pharmaceuticals
- Enrollment
- 500
- Start date
- Apr 2002
- Locations
- 48 sites, United States, Puerto Rico
- Primary endpoint
- Study in Hepatitis C